TY - JOUR
T1 - Modeling Outcomes in Children With Biliary Atresia With Native Liver After 2 Years of Age
AU - for the Childhood Liver Disease Research Network
AU - Venkat, Veena
AU - Ng, Vicky L.
AU - Magee, John C.
AU - Ye, Wen
AU - Hawthorne, Kieran
AU - Harpavat, Sanjiv
AU - Molleston, Jean P.
AU - Murray, Karen F.
AU - Wang, Kasper S.
AU - Soufi, Nisreen
AU - Bass, Lee M.
AU - Alonso, Estella M.
AU - Bezerra, Jorge A.
AU - Jensen, M. Kyle
AU - Kamath, Binita M.
AU - Loomes, Kathleen M.
AU - Mack, Cara L.
AU - Rosenthal, Philip
AU - Shneider, Benjamin L.
AU - Squires, Robert H.
AU - Sokol, Ronald J.
AU - Karpen, Saul J.
N1 - Funding Information:
Heather Van Doren, M.F.A., Senior Medical Editor with Arbor Research Collaborative for Health, provided editorial assistance on this manuscript.
Publisher Copyright:
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.
PY - 2020/12
Y1 - 2020/12
N2 - Approximately 50% of infants with biliary atresia (BA) undergoing Kasai portoenterostomy show survival with native liver (SNL) at age 2 years. Predictors of disease progression after age 2 years are unknown, despite estimates of 20%-30% undergoing liver transplant (LT) between age 2 and 18 years. We sought to address this knowledge gap by developing prognostic models in participants of the multicenter prospective National Institutes of Health-supported Childhood Liver Disease Research Network. We extracted 14 clinical and biochemical variables at age 2 years to develop two models for future outcomes: 1) LT or death (LTD) and 2) first sentinel event (SE), either new onset ascites, hepatopulmonary syndrome (HPS), or gastrointestinal (GI) bleed. A total of 240 participants, enrolled between 2004 and 2017, were followed until a median age of 5.1 years (range, 2.0-13.3 years). Of these participants, 38 underwent LT (n = 37) or death (n = 1); cumulative incidence, 23.7% (95% confidence interval [CI], 16.2%-32.0%). Twenty-seven experienced either new-onset ascites (n = 13), HPS (n = 1), or GI bleed (n = 14). One participant had ascites and GI bleed concurrently; cumulative incidence, 21.5% (95% CI, 14.2%-29.8%) by age 10 years. The Cox proportional hazard model predicted risk of LTD, using total bilirubin, albumin, platelet count, and history of either ascites or cholangitis (BA LTD model), with a C-index of 0.88 (range, 0.86-0.89). A cause-specific hazard competing risk model predicted SE using platelet count and gamma glutamyltransferase levels (BA SE model) with a C-index of 0.81 (range, 0.80-0.84). Internal model validity was assessed using Harrell’s C-index with cross-validation. Conclusion: Stratification using these models identified risk of poor outcomes in patients with BA SNL after age 2 years. The models may identify those who would benefit from enhanced clinical surveillance and prioritization in clinical trials.
AB - Approximately 50% of infants with biliary atresia (BA) undergoing Kasai portoenterostomy show survival with native liver (SNL) at age 2 years. Predictors of disease progression after age 2 years are unknown, despite estimates of 20%-30% undergoing liver transplant (LT) between age 2 and 18 years. We sought to address this knowledge gap by developing prognostic models in participants of the multicenter prospective National Institutes of Health-supported Childhood Liver Disease Research Network. We extracted 14 clinical and biochemical variables at age 2 years to develop two models for future outcomes: 1) LT or death (LTD) and 2) first sentinel event (SE), either new onset ascites, hepatopulmonary syndrome (HPS), or gastrointestinal (GI) bleed. A total of 240 participants, enrolled between 2004 and 2017, were followed until a median age of 5.1 years (range, 2.0-13.3 years). Of these participants, 38 underwent LT (n = 37) or death (n = 1); cumulative incidence, 23.7% (95% confidence interval [CI], 16.2%-32.0%). Twenty-seven experienced either new-onset ascites (n = 13), HPS (n = 1), or GI bleed (n = 14). One participant had ascites and GI bleed concurrently; cumulative incidence, 21.5% (95% CI, 14.2%-29.8%) by age 10 years. The Cox proportional hazard model predicted risk of LTD, using total bilirubin, albumin, platelet count, and history of either ascites or cholangitis (BA LTD model), with a C-index of 0.88 (range, 0.86-0.89). A cause-specific hazard competing risk model predicted SE using platelet count and gamma glutamyltransferase levels (BA SE model) with a C-index of 0.81 (range, 0.80-0.84). Internal model validity was assessed using Harrell’s C-index with cross-validation. Conclusion: Stratification using these models identified risk of poor outcomes in patients with BA SNL after age 2 years. The models may identify those who would benefit from enhanced clinical surveillance and prioritization in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85113963061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113963061&partnerID=8YFLogxK
U2 - 10.1002/hep4.1602
DO - 10.1002/hep4.1602
M3 - Article
C2 - 33305153
AN - SCOPUS:85113963061
SN - 2471-254X
VL - 4
SP - 1824
EP - 1834
JO - Hepatology Communications
JF - Hepatology Communications
IS - 12
ER -